

1 **Bat and pangolin coronavirus spike glycoprotein structures**  
2 **provide insights into SARS-CoV-2 evolution**

3 Shuyuan Zhang<sup>1,\*</sup>, Shuyuan Qiao<sup>1,\*</sup>, Jinfang Yu<sup>1,\*</sup>, Jianwei Zeng<sup>1</sup>, Sisi Shan<sup>2</sup>, Jun  
4 Lan<sup>1</sup>, Long Tian<sup>1</sup>, Linqi Zhang<sup>2</sup>, Xinquan Wang<sup>1,#</sup>

5

6 <sup>1</sup>The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation  
7 Center for Structural Biology, Beijing Frontier Research Center for Biological Structure,  
8 Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University,  
9 100084 Beijing, China

10 <sup>2</sup>Center for Global Health and Infectious Diseases, Comprehensive AIDS Research Center,  
11 Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua  
12 University, Beijing, China

13

14 \*These authors contributed equally to this work

15 #Correspondence: [xinquanwang@mail.tsinghua.edu.cn](mailto:xinquanwang@mail.tsinghua.edu.cn) (X.W.)

16 **Abstract**

17 In recognizing the host cellular receptor and mediating fusion of virus and cell  
18 membranes, the spike (S) glycoprotein of coronaviruses is the most critical viral  
19 protein for cross-species transmission and infection. Here we determined the cryo-EM  
20 structures of the spikes from bat (RaTG13) and pangolin (PCoV\_GX) coronaviruses,  
21 which are closely related to SARS-CoV-2. All three receptor-binding domains (RBDs)  
22 of these two spike trimers are in the “down” conformation, indicating they are more  
23 prone to adopt this receptor-binding inactive state. However, we found that the  
24 PCoV\_GX, but not the RaTG13, spike is comparable to the SARS-CoV-2 spike in  
25 binding the human ACE2 receptor and supporting pseudovirus cell entry. Through  
26 structure and sequence comparisons, we identified critical residues in the RBD that  
27 underlie the different activities of the RaTG13 and PCoV\_GX/SARS-CoV-2 spikes  
28 and propose that N-linked glycans serve as conformational control elements of the  
29 RBD. These results collectively indicate that strong RBD-ACE2 binding and efficient  
30 RBD conformational sampling are required for the evolution of SARS-CoV-2 to gain  
31 highly efficient infection.

## 32 **Introduction**

33 Zoonotic transmission of novel coronaviruses pose a tremendous threat to human  
34 health, as evidenced by the emergence of SARS-CoV in 2002-2003, MERS-CoV in  
35 2012 and SARS-CoV-2 since the end of 2019<sup>1-5</sup>. SARS-CoV-2 is responsible for the  
36 ongoing global COVID-19 pandemic, which has caused millions of infections and  
37 hundreds of thousands of deaths worldwide  
38 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>)  
39 . Current data suggest that similar to SARS-CoV and MERS-CoV<sup>6</sup>, SARS-CoV-2  
40 likely originated in bats and eventually spread to humans following evolution in  
41 intermediate hosts. Coronavirus RaTG13, detected in the horseshoe bat *Rhinolophus*  
42 *affinis* in China's Yunnan province, was identified as the closest relative of  
43 SARS-CoV-2<sup>5</sup>. It shares 96.2% sequence identity with the SARS-CoV-2 genome,  
44 reflecting the likely origin of SARS-CoV-2 in bats<sup>5</sup>. Pangolin coronaviruses (PCoV)  
45 closely related to SARS-CoV-2 have also been identified in smuggled Malayan  
46 pangolins (*Manis javanica*) in China's Guangxi (GX) and Guangdong (GD) provinces.  
47 Analyses of PCoV\_GX and PCoV\_GD genome sequences indicated a high level of  
48 similarity with SARS-CoV-2 (85.5% to 92.4% sequence identity)<sup>7-10</sup>. Whether  
49 pangolins are intermediate hosts or a natural reservoir for SARS-CoV-2 remains a  
50 topic of debate, and it is still unclear how SARS-COV-2 evolved to infect humans.

51 The spike (S) glycoprotein of coronaviruses forms a trimer, which plays a critical  
52 role in host cell attachment and entry by recognizing its cellular receptor and  
53 mediating membrane fusion. Consequently, the spike protein, particularly its  
54 receptor-binding domain (RBD), is the principal player in determining the host range  
55 of coronaviruses<sup>11</sup>. SARS-CoV-2 utilizes human ACE2 (hACE2) as an essential  
56 cellular receptor for infection<sup>5,12</sup>. Complex structural determinations have revealed the  
57 interactions between SARS-CoV-2 RBD and hACE2 at an atomic level<sup>13-16</sup>. Cryo-EM  
58 studies revealed that the SARS-CoV-2 S trimer, similar to that of SARS-CoV, needs  
59 to have at least one RBD in an “up” conformation to bind hACE2<sup>17-23</sup>. Therefore, a  
60 spike trimer with all three RBDs “down” is in a receptor-binding inactive state, and  
61 the conformational change of at least one RBD from “down” to “up” switches the

62 spike trimer to a receptor-binding active state<sup>18</sup>. The spike and RBD of RaTG13 and  
63 SARS-CoV-2 share 97.5% and 89.2% amino acid sequence identity, respectively.  
64 Similar to RaTG13, PCoV\_GX (GenBank: QIA48614.1) shares 92.3% and 86.7%  
65 amino acid sequence identity with the SARS-CoV-2 spike and RBD. In contrast,  
66 PCoV\_GD (GenBank: QLR06867.1) and SARS-CoV-2 have greater amino acid  
67 sequence identity in the RBD (96.9%) than in the spike protein (89.6%). Consistently,  
68 the RBD of PCoV\_GD has demonstrated stronger binding to hACE2 than the RBD of  
69 RaTG13, and hACE2 also supported more efficient cell entry of PCoV\_GD than  
70 RaTG13 pseudoviruses<sup>24</sup>. Data have not been reported regarding the binding of  
71 PCoV\_GX spike and its RBD to hACE2 or whether hACE2 supports PCoV\_GX  
72 pseudovirus cell entry.

73 Here we report the cryo-EM structures of RaTG13 and PCoV\_GX spikes at 2.48  
74 Å and 2.93 Å resolution, respectively. These two spikes have all three RBDs in the  
75 “down” conformation. Our structural comparisons of RaTG13, PCoV\_GX and  
76 SARS-CoV-2 S proteins, coupled with functional data on hACE2 binding and  
77 pseudovirus cell entry, provide important insights into the evolution and  
78 cross-transmission of SARS-CoV-2.

79

## 80 **Results**

### 81 **Protein expression and structure determination**

82 The cDNAs encoding the PCoV\_GX (GenBank: QIA48614.1) and RaTG13  
83 (GenBank: QHR63300.2) spike proteins were synthesized with codon optimization  
84 for recombinant expression. The PCoV\_GX ectodomain (residues 1-1205) was cloned  
85 into the pCAG vector and the RaTG13 ectodomain (residues 1-1209) into the  
86 pFastBac-Dual vector. Both constructs include a C-terminal foldon tag for  
87 trimerization, a Strep tag for purification, and the ‘2P’ mutations for protein  
88 stabilization (K980P and V981P for PCoV\_GX; K982P and V983P for RaTG13).  
89 After purification of PCoV\_GX spike from FreeStyle 293-F cells and that of RaTG13

90 from Hi5 insect cells, both proteins existed as heavy glycosylated homotrimers with  
91 no cleavage into the S1 and S2 subunits by endogenous proteases (Fig. S1). Cryo-EM  
92 images were recorded using a FEI Titan Krios microscope operating at 300 KV with a  
93 Gatan K3 Summit direct electron detector. For the PCoV\_GX and RaTG13 spike  
94 trimers, ~700,000 and ~450,000 particles, respectively, were subjected to 2D  
95 classification, and a total of 263,842 and 99,241 particles were selected and subjected  
96 to 3D refinement with C3 symmetry to generate density maps (Fig. S2). The overall  
97 density maps were solved to 2.48 Å for the PCoV\_GX spike and 2.93 Å for the  
98 RaTG13 spike (gold-standard Fourier shell correlation = 0.143) (Fig. S3). The  
99 atomic-resolution density maps enabled us to build nearly all residues of the  
100 PCoV\_GX spike (residues 14-1138) with 84 N-linked glycans (Fig. S4). The refined  
101 RaTG13 spike model contains residues 14-1133 with seven breaks (residues 19-23,  
102 67-80, 144-156, 176-186, 243-264, 677-685 and 824-830) and 54 N-linked glycans  
103 (Fig. S4). Data collection and refinement statistics for these two structures are listed  
104 in Table S1.

105

## 106 **Overall structures of RaTG13 and PCoV\_GX spikes**

107 The overall structures of homotrimeric RaTG13 and PCoV\_GX spikes resemble the  
108 previously reported pre-fusion structures of coronavirus spikes (Fig. 1A). Both spikes  
109 have a mushroom-like shape (~150 Å in height and ~120 Å in width), consisting of a  
110 cap mainly formed by  $\beta$ -strands and a stalk mainly formed by  $\alpha$ -helices (Fig. 1A).  
111 Like other coronaviruses, the RaTG13 and PCoV\_GX spike monomers are composed  
112 of the S1 and S2 subunits with a protease cleavage site between them (Fig. 1B,1C).  
113 The structural components of the spike include the N-terminal domain (NTD), RBD  
114 (also called the C-terminal domain, CTD), subdomain 1 (SD1) and subdomain 2 (SD2)  
115 in the S1 subunit; and the upstream helix (UH), fusion peptide (FP), connecting  
116 region (CR), heptad repeat 1 (HR1), central helix (CH),  $\beta$ -hairpin (BH), subdomain 3  
117 (SD3) and heptad repeat 2 (HR2) in the S2 subunit (Fig. 1D, Fig. S5).

118 RaTG13 and PCoV\_GX spikes have the typical  $\beta$ -coronavirus structural  
119 features<sup>25</sup>. Their NTDs have a core consisting of three  $\beta$ -sheets plus one helix and a  
120 ceiling structure above the core (Fig. S6). Three conserved disulfide bonds that are  
121 found in other  $\beta$ -coronavirus NTDs are also present in the NTDs of RaTG13  
122 (15C-136C, 131C-166C and 291C-301C) and PCoV\_GX (15C-134C, 129C-164C and  
123 289C-299C) (Fig. S6). The RaTG13 and PCoV\_GX RBDs adopt an architecture  
124 similar to that of other  $\beta$ -coronavirus RBDs, with a  $\beta$  sheet core and an inserted loop  
125 called a receptor-binding motif (RBM) (Fig. 2A). Detailed structural descriptions and  
126 comparisons of these two RBDs are presented in the next section. The remaining SD1  
127 and SD2 domains in the S1 subunit and the S2 subunits of RaTG13 and PCoV\_GX  
128 are also structurally conserved and similar to those of SARS-CoV-2.

129

### 130 **Structures and hACE2 binding of the RBDs**

131 Most  $\beta$ -coronaviruses utilize the RBD to specifically bind the host receptor.  
132 Compared to other structural components in the spike, the RBD harbors the most  
133 sequence and structure variations across different  $\beta$ -coronaviruses and thus has  
134 important implications for viral evolution and cross-species transmission. The  
135 RaTG13 and PCoV\_GX RBD cores are comprised of a twisted five-stranded  
136 antiparallel  $\beta$  sheet ( $\beta$ 1,  $\beta$ 2,  $\beta$ 3,  $\beta$ 4 and  $\beta$ 7) with connecting loops and helices (Fig.  
137 2A). The RBM, a long loop with two short  $\beta$  strands ( $\beta$ 5 and  $\beta$ 6), is inserted between  
138 the  $\beta$ 4 and  $\beta$ 7 strands (Fig. 2A). Besides three disulfide bonds in the core (336C-361C,  
139 379C-432C and 391C-525C in RaTG13; 334C-359C, 377C-430C and 389C-523C in  
140 PCoV\_GX) that stabilize the  $\beta$  sheet, the RaTG13 and PCoV\_GX RBDs also have an  
141 additional disulfide bond (480C-488C in RaTG13 and 478C-486C in PCoV\_GX) that  
142 connects the loop at the distal end of the RBM (Fig. 2A). The overall structures of the  
143 RaTG13/PCoV\_GX and SARS-CoV-2 RBDs are highly similar (Fig. 2B). The rmsd  
144 for aligned C $\alpha$  atoms is 0.91 Å between the RaTG13 and SARS-CoV-2 RBDs and  
145 0.59 Å between the PCoV\_GX and SARS-CoV-2 RBDs.

146 We measured the binding affinities of hACE2 with the RBDs of RaTG13,

147 PCoV\_GX and SARS-CoV-2 using surface plasmon resonance (SPR). The  
148 PCoV\_GX and SARS-CoV-2 RBDs bound to hACE2 with comparable affinities of  
149 2.7 nM and 3.9 nM, respectively. However, the RaTG13 RBD bound to hACE2 with  
150 a much weaker affinity of 216 nM (Fig. 3A). Sequence comparisons showed that both  
151 the RaTG13 and PCoV\_GX RBMs share 75.3% amino acid sequence identity with  
152 the RBM of SARS-CoV-2. Of the 16 residues in the SARS-CoV-2 RBM involved  
153 with ACE2 binding, ten are conserved in RaTG13, PCoV\_GX and SARS-CoV-2 (Fig.  
154 3B). The other six SARS-CoV-2 residues that are not conserved in both RaTG13 and  
155 PCoV\_GX are Y449, F486, Q493, Q498, N501 and Y505 (Fig. 3B). Except for F486,  
156 which is replaced by a leucine in RaTG13 and PCoV\_GX, these residues (Y449,  
157 Q493, Q498, N501 and Y505) in the SARS-CoV-2 RBM form a patch that has  
158 significant hydrophilic interactions with hACE2 (Fig. 3B, Fig. S7). Of these five  
159 positions, SARS-CoV-2 Y449 forms two hydrogen bonds with hACE2 D38 and Q42  
160 upon binding. This tyrosine is conserved in the PCoV\_GX RBD but is replaced by a  
161 phenylalanine in the RaTG13 RBD, which would disrupt the hydrogen-bonding  
162 interactions (Fig. 3C, Fig. S7). Similarly, SARS-CoV-2 Y505 forms two hydrogen  
163 bonds with hACE2 E37 and R393. This residue is conserved in PCoV\_GX RBD,  
164 perhaps having a similar effect in facilitating hACE2 binding, whereas the histidine  
165 found at this site in the RaTG13 RBD would alter interactions with hACE2 (Fig. 3C,  
166 Fig. S7). We therefore propose that Y449 and Y505 are two of the principal sites that  
167 contribute to the weaker binding of the RaTG13 RBD with hACE2 compared to that  
168 of the RBDs of PCoV\_GX and SARS-CoV-2.

169

### 170 **Conformations and hACE2 binding of the RaTG13 and PCoV\_GX spikes**

171 As described above, at least one of the RBDs in the SARS-CoV-2 spike trimer must  
172 adopt an "up" conformation in order to bind hACE2. By cryo-EM, we only captured  
173 conformational states of RaTG13 and PCoV\_GX spikes with all three RBDs in the  
174 "down" position. Structures of SARS-CoV-2 spike trimer with all three RBDs in the  
175 "down" conformation were previously determined (PDB IDs: 6VXX and 6ZGE)<sup>19,21</sup>.  
176 In 6VXX, one of the SARS-CoV-2 RBDs exhibits contacts with 11 residues and the

177 N165/N234-linked glycans from the counter-clockwise monomer and 5 residues from  
178 the clockwise monomer (Fig. 4A and 4B, Table S2). In 6ZGE, the three “down”  
179 RBDs are more compactly packed, with one RBD having interactions with 35  
180 residues and the N165/N234-linked glycans of the two neighboring monomers (Fig.  
181 4A and 4B, Table S2). In the RaTG13 spike, one RBD contacts 27 residues and the  
182 N165/N234/N370-linked glycans from the counter-clockwise monomer, and 13  
183 residues from the clockwise monomer with a distance cutoff of 4.0 Å (Fig. 4A and 4B,  
184 Table S2). A nearly identical packing of RBDs was also observed in a recently  
185 reported RaTG13 spike structure (PDB ID:6ZGF)<sup>21</sup>. In the PCoV\_GX spike, the  
186 number of RBD-contacting residues is 27 from the counter-clockwise monomer and  
187 16 from the clockwise monomer. The N163/N232/N368-linked glycans from the  
188 counter-clockwise monomer are also involved in contact with the RBD (Fig. 4B,  
189 Table S2). Therefore, regarding RBD packing, the RaTG13 and PCoV\_GX spikes are  
190 more similar to the SARS-CoV-2 spike structure 6ZGE than 6VXX.

191 Unlike in our study, the cryo-EM studies which determined the structures of  
192 6ZGE and 6VXX did capture the SARS-CoV-2 spikes adopting a more loose state  
193 with one “up” RBD. Our observations of all three RBDs only in the “down” position  
194 in the RaTG13 and PCoV\_GX spikes suggests they are more prone to adopt the  
195 receptor-binding inactive state. Considering that the number of protein-protein  
196 interactions around the “down” RBD is nearly the same among the RaTG13,  
197 PCoV\_GX and SARS-CoV-2 (6ZGE) spikes, glycans may play an important role in  
198 how efficiently the RBD can sample different conformations. Of note, we observed  
199 contacts between the RBD and three neighboring N-linked glycans, spatially  
200 positioned at three vertices of a triangle, in the RaTG13 and PCoV\_GX spikes (Fig.  
201 4B). Although the SARS-CoV-2 spike also has three asparagine residues (N165,  
202 N234 and N370) at these same positions, N370 is not a glycosylation site in the  
203 SARS-CoV-2 spike and thus glycans contacting the RBD are not observed at this  
204 position (Fig. 4B).

205 To further our findings, we also measured the binding affinities of hACE2 with  
206 the spikes of RaTG13, PCoV\_GX and SARS-CoV-2. Interestingly, we found that



207 despite exhibiting only a receptor-binding inactive conformation in the cryo-EM  
208 images, the PCoV\_GX spike bound hACE2 with an affinity of 130 nM, comparable  
209 to the 105 nM affinity of the SARS-CoV-2 spike (Fig. 5A). The binding of RaTG13  
210 spike to hACE2 was weaker, with an affinity of 600 nM. We tested the entry of  
211 RaTG13, PCoV\_GX and SARS-CoV-2 pseudoviruses into HEK293 cells expressing  
212 hACE2. Consistently, the PCoV\_GX and SARS-CoV-2 pseudoviruses had  
213 comparable entry efficiency, whereas the RaTG13 pseudovirus exhibited little to no  
214 entry (Fig. 5B).

215 To capture the hACE2-bound state of the RaTG13 and PCoV\_GX spikes, we  
216 mixed spike and ACE2 at a 1:4 molar ratio and performed negative-staining EM. The  
217 2D classification did not show particles with bound hACE2 for the RaTG13 spike, but  
218 ~9% of the PCoV\_GX particles were bound to hACE2. After treating the PCoV\_GX  
219 spike with trypsin for 2 hours, the ratio of hACE2-bound particles increased to 20%  
220 (Fig. 5C). These results further support that the conformational switch of the spike is  
221 a dynamic equilibrium process and that binding of hACE2 would capture the spike  
222 with “up” RBDs and shift the process towards more spikes ready for receptor binding  
223 and membrane fusion.

224

## 225 **Discussion**

226 Coronavirus spike glycoproteins recognize their host cellular receptor and  
227 mediate membrane fusion for entry, thereby functioning as the most critical  
228 coronavirus protein in determining viral evolution and cross-species transmission. In  
229 this study, cryo-EM structures of RaTG13 and PCoV\_GX spikes were determined at  
230 atomic resolution. Our comparisons of the structures of the RaTG13, PCoV\_GX and  
231 SARS-COV-2 spikes, the strength of their hACE2-binding, and their efficiency in  
232 facilitating pseudovirus cell entry provide important insights into the evolution and  
233 cross-species transmission of SARS-CoV-2.

234 Our structural determinations of the RaTG13 and PCoV\_GX spikes showed that  
235 the RBDs of these two coronaviruses are highly similar to that of SARS-CoV-2.

236 However, our SPR experiments showed that only PCoV\_GX RBD exhibited a  
237 hACE2-binding affinity comparable to SARS-CoV-2 RBD, whereas RaTG13 RBD  
238 demonstrated far weaker binding. Sequence alignments showed that variation at six  
239 residues (SARS-CoV-2 Y449, F486, Q493, Q498, N501 and Y505) were responsible  
240 for the these differences in hACE2-binding among the RaTG13, PCoV\_GX and  
241 SARS-CoV2 RBDs. The residues Y449, Q493, Q498, N501 and Y505 are especially  
242 important, clustering together to form a patch on the SARS-CoV-2 RBD that has  
243 significant interactions with hACE2. We further pinpointed amino acid changes at  
244 two positions (Y449 and Y505) only seen in the RaTG13, and not the PCoV\_GX,  
245 RBD that may account for the weaker binding we observed between hACE2 and the  
246 RaTG13 RBD. Our findings and conclusions are supported by recent reports of  
247 adapted and remodeled SARS-CoV-2 strains utilized in mouse model studies. Gu et al.  
248 reported an adapted SARS-CoV-2 strain with increased infectivity in mice that has a  
249 N501Y mutation in the RBD<sup>26</sup>. Dinnon et al. remodeled the SARS-COV-2 RBD at  
250 two sites (Q498Y and P499T) to facilitate efficient binding to mouse ACE2,  
251 producing a recombinant virus that can effectively utilize mouse ACE2 for entry<sup>27</sup>.  
252 These positions are within the patch we observed and suggest their importance in the  
253 binding capabilities of the RaTG13, PCoV\_GX and SARS-CoV-2 RBDs to human  
254 ACE2. We further propose that the patch containing Y449, Q493, Q498, N501 and  
255 Y505 plays a critical role in the evolution of the SARS-CoV-2 RBD, promoting  
256 especially tight binding to hACE2 and impacting the varying affinities observed  
257 between the RBD and ACE2 orthologs in wild and domestic animals<sup>24,28</sup>.

258 The spikes of diverse coronaviruses infecting humans, mice, swine and other  
259 hosts have been structurally determined<sup>25</sup>. Current data show that the spikes of only  
260 the highly pathogenic human coronavirus SARS-CoV, MERS-CoV and SARS-CoV-2  
261 have a unique structural feature, with the three RBDs in the trimer adopting “down”  
262 or “up” conformations<sup>17,19-21,29</sup>. Structure determination of the spike-receptor complex  
263 has provided further confirmation that the “up” conformation is required for receptor  
264 binding, indicating that the sampling of “down” and “up” conformations by at least  
265 one RBD is a prerequisite for receptor binding<sup>18,22,23</sup> in addition to specific

266 interactions between the RBD and cellular receptor. In our cryo-EM study, the  
267 RaTG13 and PCoV\_GX spikes exhibited only a receptor-binding inactive state, with  
268 all three RBDs adopting the “down” conformation. Another group had the same  
269 conclusion in a recent structural determination of the RaTG13 spike<sup>21</sup>. However, in  
270 studies of the SARS-CoV-2 spike, the protein seemed to have two conformations,  
271 even in the receptor-binding inactive state, with one having more compact packing of  
272 the three “down” RBDs than the other<sup>19,21</sup>. We found that the spikes of RaTG13 and  
273 PCoV\_GX are more similar to the SARS-CoV-2 spike with tight RBD packing. The  
274 molecular basis of the more efficient conformational sampling of the SARS-CoV-2  
275 RBD is still not well understood. We observed three N-linked glycans (SARS-CoV-2  
276 positions: N165, N234 and N370) contact the RBD in the RaTG13 and PCoV\_GX  
277 spikes, whereas N370 is not a glycosylation site in the SARS-CoV-2 spike. The  
278 absence of glycans linked to N370 may contribute to the more flexible RBDs of the  
279 SARS-CoV-2 spike. This is also supported by a recent study showing that mutation of  
280 SARS-CoV-2 N165 resulted in an increase of “up” RBDs, suggesting that glycans  
281 serve as a conformational control element of the RBD<sup>30</sup>. We also cannot exclude other  
282 factors, such as the furin site that enables cleavage of the spike protein into the S1 and  
283 S2 subunits during biogenesis, may also contribute to the RBD flexibility.

284 The RaTG13 and PCoV\_GX spikes and their RBDs all bound hACE2 in our SPR  
285 experiments, although both the RBD and spike of PCoV\_GX exhibited higher binding  
286 affinities than those of RaTG13. These results suggest that RaTG13 and PCoV\_GX  
287 spikes can also spontaneously sample “up” RBD, which is essential for hACE2  
288 binding. The reason for not observing these conformations in our cryo-EM study may  
289 be due to the ratio of RaTG13 and PCoV\_GX spike particles adopting this state being  
290 too low. Interestingly, the PCoV\_GX spike bound to hACE2 with an affinity  
291 comparable to that of the SARS-CoV-2 spike and also had similar efficiency in cell  
292 entry. In contrast, the RaTG13 spike was much weaker in binding hACE2 and  
293 mediating cell entry. We also confirmed the binding of PCoV\_GX spike to hACE2 by  
294 negative-staining EM.

295 Based on all these results, we propose that the tight RBD-hACE2 binding we

296 observed is the most critical factor in determining the varied cell-entry efficiency  
297 among RaTG13, PCoV\_GX and SARS-COV-2. This and the RBD “down” to “up”  
298 conformational change are both required for the evolution of SARS-CoV-2 to gain  
299 highly efficient transmission capability.

## 300 **Materials and Methods**

### 301 **Protein expression and purification**

302 The cDNAs encoding the SARS-CoV-2 spike (GenBank: YP\_009724390.1),  
303 PCoV\_GX spike (GenBank: QIA48614.1) and RaTG13 spike (GenBank:  
304 QHR63300.2) were synthesized with codons optimized for human expression. The  
305 SARS-CoV-2 spike ectodomain (1-1121) and PCoV\_GX ectodomain (1-1205) were  
306 cloned into the pCAG vector separately, and the RaTG13 spike ectodomain (1-1209)  
307 was cloned into the pFastBac-Dual vector (Invitrogen). All the spike constructs  
308 included a C-terminal foldon tag for trimerization, a Strep tag for purification and  
309 ‘2P’ mutations<sup>31</sup> (K986P and V987P for SARS-CoV-2, K980P and V981P for  
310 PCoV\_GX, K982P and V983P for RaTG13).

311 The human ACE2 extracellular domain (19-615), SARS-CoV-2 RBD (333-527),  
312 PCoV\_GX RBD (331-524) and RaTG13 RBD (333-526) were inserted into the  
313 pFastBac-Dual vector, with an N-terminal gp67 signal peptide for secretion and a  
314 C-terminal 6 × his tag for purification.

315 The SARS-CoV-2 and PCoV\_GX spike ectodomains were expressed in  
316 FreeStyle 293-F cells. Cell cultures were transfected with 1mg of plasmid per liter of  
317 culture at a density of  $2 \times 10^6$ /ml using polyethylenimine (Sigma). The supernatants  
318 were collected 72 hours later. RaTG13 spike, SARS-CoV-2 RBD, PCoV\_GX RBD,  
319 RaTG13 RBD and ACE2 were produced in Hi5 insect cell using the Bac-to-Bac  
320 baculovirus system (Invitrogen). Briefly, the amplified high-titer baculoviruses were  
321 used to infect Hi5 cells at a density of  $2 \times 10^6$ /ml, and the supernatants were harvested  
322 after 60 hours. SARS-CoV-2, PCoV\_GX and RaTG13 spikes were captured by  
323 StrepTactin beads (IBA) and further purified by gel-filtration chromatography using a  
324 Superose 6 column (GE Healthcare) with buffer containing 20mM Tris-HCl (pH 8.0)  
325 and 150mM NaCl. hACE2, SARS-CoV-2 RBD, PCoV\_GX RBD and RaTG13 RBD  
326 were purified by sequentially applying Ni-NTA resin (GE Healthcare) to a Superdex  
327 200 column (GE Healthcare) with HBS buffer (10 mM HEPES, pH 7.2, 150 mM  
328 NaCl).

329

### 330 **Surface plasmon resonance experiments**

331 Running buffer composed of 10 mM HEPES, pH 7.2, 150 mM NaCl and 0.05% (v/v)  
332 Tween-20 was used during the analysis, and all proteins were exchanged to the same  
333 buffer. hACE2 was immobilized on a CM5 sensorchip (GE Healthcare) at around 700  
334 response units using Biacore T200 (GE Healthcare). The blank channel of the chip  
335 was used as the negative control. Serial dilutions of the SARS-CoV-2, PCoV\_GX and  
336 RaTG13 spikes and their respective RBDs were flowed through the ACE2  
337 immobilized CM5 chip sequentially. The resulting data were analyzed using Biacore  
338 Evaluation Software (GE Healthcare) by fitting to a 1:1 binding model.

339

### 340 **Pseudovirus entry assays**

341 SARS-CoV-2, PCoV\_GX and RaTG13 pseudoviruses were generated by  
342 co-transfection of human immunodeficiency virus backbones expressing firefly  
343 luciferase (pNL43R-E-luciferase) and pcDNA3.1 (Invitrogen) expression vectors  
344 encoding the respective spike protein into 293T cells (ATCC). Viral supernatants  
345 were collected 48-72 h later. The concentration of the harvested pseudotyped virions  
346 was normalized by a p24 ELISA kit (Beijing Quantobio Biotechnology Co., Ltd.,  
347 China) before infecting hACE2-transfected 293T cells. The infected cells were lysed  
348 24 h after infection and viral entry efficiency was quantified by comparing the  
349 luciferase activity among pseudotyped viruses.

350

### 351 **Trypsin treatment of the PCoV\_GX and RaTG13 spike glycoproteins**

352 L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin was  
353 added to the purified PCoV\_GX spike at a mass ratio of 1:100 in HBS buffer and  
354 incubated at room temperature for 2 hours. SDS-PAGE was performed to determine  
355 that the spikes were fully cleaved into S1 and S2 fragments. The digestion reaction  
356 was stopped by applying the mixture to negative staining.

357

### 358 **Negative stain EM**

359 The RaTG13, PCoV\_GX and trypsin-cleaved PCoV\_GX spikes (0.05mg/ml) were  
360 separately mixed with hACE2 on ice for a few minutes at a molar ratio of 1:4, and  
361 then deposited onto glow-discharged grids with a continuous carbon layer (Beijing  
362 Zhongjingkeyi Technology Co., Ltd.). Excess sample was removed using filter paper  
363 after 1 minute of incubation on the grid, then washed twice, incubated with 5  $\mu$ l of 2%  
364 uranyl acetate (UA) solution for another minute, and finally blotted with filter paper.  
365 These grids were examined under an FEI Tecnai Spirit electron microscope equipped  
366 with an FEI Eagle 4k CCD camera. Images were manually collected at 52,000  
367 magnification with a defocus range between 1.5-1.8  $\mu$ m, corresponding to a pixel size  
368 of 2.07  $\text{\AA}$ . Appropriately, 50 pieces of images were collected for each sample. Image  
369 format converting was conducted by EMAN<sup>32</sup>. Particle auto-picking, particle  
370 extraction and 2D classification were performed in RELION<sup>33</sup>.

371

### 372 **Cryo-EM sample preparation and data collection**

373 Aliquots of spike ectodomains (4 $\mu$ l, 0.3mg/ml, in buffer containing 20mM Tris-HCl  
374 pH 8.0, 150mM NaCl) were applied to glow-discharged holey carbon grids  
375 (Quantifoil, Au 300 mesh, R1.2/1.3) and grids with a layer of continuous ultrathin  
376 carbon film (Ted Pella, Inc.). The grids were then blotted and plunge-frozen into  
377 liquid ethane using an FEI Vitrobot Mark IV.

378 Images were recorded using FEI Titan Krios microscope operating at 300 kV  
379 with a Gatan K3 Summit direct electron detector (Gatan Inc.) at Tsinghua University.  
380 The automated software (AutoEMation) was used to collect 3963 movies for  
381 PCoV\_GX and 1889 movies for RaTG13 at 81,000 magnification at a defocus range  
382 between 1.5-1.8  $\mu$ m. Each movie has a total accumulated exposure of 50  $e^-/\text{\AA}^2$   
383 fractionated in 32 frames of 175 ms exposure. The final image was bin averaged to  
384 give a pixel size of 1.0825  $\text{\AA}$ . Data collection statistics are summarized in Table S1.

385

### 386 **Cryo-EM data processing**

387 Motion Correction (MotionCo2<sup>34</sup>), CTF-estimation (GCTF<sup>35</sup>) and non-templated particle  
388 picking (Gautomatch, <http://www.mrc-lmb.cam.ac.uk/kzhang/>) were automatically

389 executed by TsingTitan.py program. Sequential data processing was carried out on  
390 RELION. Initially, ~700,000 particles for PCoV\_GX and ~450,000 particles for  
391 RaTG13 were subjected to 2D classification. After two or three additional 2D  
392 classification, the best selected 474,499 particles for PCoV\_GX and 107,274 particles  
393 for RaTG13 were applied for initial model and 3D classification.

394 For PCoV\_GX, the best class (397,362 particles) from 3D classification yielded a  
395 resolution of 3.14 Å (with C3 symmetry). To improve map density, especially NTD  
396 and glycosides, particles were expanded with C3 symmetry, and then subjected to  
397 local search classification. The particles of best class from local search classification  
398 were further applied to CTF refinement with C3 symmetry and Bayesian polishing,  
399 which improved the resolution to 2.71 Å and 2.48 Å, respectively. Meanwhile, the  
400 selected particles were subjected to focused classification with an adapted mask on  
401 NTD, and then further applied to 3D-refinement, CTF refinement and Bayesian  
402 polishing to reach a resolution of 3.64 Å. Additional 3D classification and Bayesian  
403 polishing resulted in the NTD map at a resolution of 3.68 Å with better quality. Three  
404 copies of NTD maps were fitted onto the whole structure map using Chimera, then  
405 combined together using PHENIX combine\_focused\_maps.

406 For RaTG13, the best class (99,241 particles) from 3D classification were  
407 subjected to 3D auto-refine with C3 symmetry to generate a density map with a  
408 resolution of 2.93 Å.

409 The reported resolutions were estimated with a gold-standard Fourier shell  
410 correlation (FSC) cutoff of 0.143 criterion. Local resolution variations were estimated  
411 using ResMap<sup>36</sup>. Data processing statistics are summarized in Table S1.

412

### 413 **Model building and refinement**

414 The initial model of PCoV\_GX and RaTG13 spikes were generated using the  
415 SWISS-MODEL<sup>37</sup> and fit into the map using UCSF Chimera<sup>38</sup>. Manual model  
416 rebuilding was carried out using Coot<sup>39</sup> and refined with PHENIX real-space  
417 refinement<sup>40</sup>. The quality of the final model was analyzed with Molprobit<sup>41</sup> and



418 EMRinger<sup>42</sup>. The validation statistics of the structural models are summarized in  
419 Table S1.

## 420 References

- 421 1 Ksiazek, T. G. *et al.* A novel coronavirus associated with severe acute  
422 respiratory syndrome. *N Engl J Med* **348**, 1953-1966,  
423 doi:10.1056/NEJMoa030781 (2003).
- 424 2 Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. &  
425 Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia  
426 in Saudi Arabia. *N Engl J Med* **367**, 1814-1820, doi:10.1056/NEJMoa1211721  
427 (2012).
- 428 3 Wu, F. *et al.* A new coronavirus associated with human respiratory disease in  
429 China. *Nature* **579**, 265-269, doi:10.1038/s41586-020-2008-3 (2020).
- 430 4 Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China,  
431 2019. *N Engl J Med* **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
- 432 5 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of  
433 probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7  
434 (2020).
- 435 6 Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses.  
436 *Nat Rev Microbiol* **17**, 181-192, doi:10.1038/s41579-018-0118-9 (2019).
- 437 7 Lam, T. T. *et al.* Identifying SARS-CoV-2-related coronaviruses in Malayan  
438 pangolins. *Nature* **583**, 282-285, doi:10.1038/s41586-020-2169-0 (2020).
- 439 8 Xiao, K. *et al.* Isolation of SARS-CoV-2-related coronavirus from Malayan  
440 pangolins. *Nature* **583**, 286-289, doi:10.1038/s41586-020-2313-x (2020).
- 441 9 Liu, P. *et al.* Are pangolins the intermediate host of the 2019 novel  
442 coronavirus (SARS-CoV-2)? *PLoS Pathog* **16**, e1008421,  
443 doi:10.1371/journal.ppat.1008421 (2020).
- 444 10 Zhang, T., Wu, Q. & Zhang, Z. Probable Pangolin Origin of SARS-CoV-2  
445 Associated with the COVID-19 Outbreak. *Curr Biol* **30**, 1346-1351 e1342,  
446 doi:10.1016/j.cub.2020.03.022 (2020).
- 447 11 Graham, R. L. & Baric, R. S. Recombination, reservoirs, and the modular  
448 spike: mechanisms of coronavirus cross-species transmission. *J Virol* **84**,  
449 3134-3146, doi:10.1128/JVI.01394-09 (2010).
- 450 12 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and  
451 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**,  
452 271-280 e278, doi:10.1016/j.cell.2020.02.052 (2020).
- 453 13 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain  
454 bound to the ACE2 receptor. *Nature* **581**, 215-220,  
455 doi:10.1038/s41586-020-2180-5 (2020).
- 456 14 Yan, R. *et al.* Structural basis for the recognition of SARS-CoV-2 by  
457 full-length human ACE2. *Science* **367**, 1444-1448,  
458 doi:10.1126/science.abb2762 (2020).
- 459 15 Wang, Q. *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by

- 460 Using Human ACE2. *Cell* **181**, 894-904 e899, doi:10.1016/j.cell.2020.03.045  
461 (2020).
- 462 16 Shang, J. *et al.* Structural basis of receptor recognition by SARS-CoV-2.  
463 *Nature* **581**, 221-224, doi:10.1038/s41586-020-2179-y (2020).
- 464 17 Gui, M. *et al.* Cryo-electron microscopy structures of the SARS-CoV spike  
465 glycoprotein reveal a prerequisite conformational state for receptor binding.  
466 *Cell Res* **27**, 119-129, doi:10.1038/cr.2016.152 (2017).
- 467 18 Song, W., Gui, M., Wang, X. & Xiang, Y. Cryo-EM structure of the SARS  
468 coronavirus spike glycoprotein in complex with its host cell receptor ACE2.  
469 *PLoS Pathog* **14**, e1007236, doi:10.1371/journal.ppat.1007236 (2018).
- 470 19 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2  
471 Spike Glycoprotein. *Cell* **181**, 281-292 e286, doi:10.1016/j.cell.2020.02.058  
472 (2020).
- 473 20 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion  
474 conformation. *Science* **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).
- 475 21 Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein  
476 structures inform on virus evolution and furin-cleavage effects. *Nat Struct Mol*  
477 *Biol* **27**, 763-767, doi:10.1038/s41594-020-0468-7 (2020).
- 478 22 Zhou, T. *et al.* A pH-dependent switch mediates conformational masking of  
479 SARS-CoV-2 spike. *bioRxiv*, doi:10.1101/2020.07.04.187989 (2020).
- 480 23 Benton, D. J. *et al.* Receptor binding and priming of the spike protein of  
481 SARS-CoV-2 for membrane fusion. *Nature*, doi:10.1038/s41586-020-2772-0  
482 (2020).
- 483 24 Li, Y. *et al.* SARS-CoV-2 and three related coronaviruses utilize multiple  
484 ACE2 orthologs and are potently blocked by an improved ACE2-Ig. *J Virol*,  
485 doi:10.1128/JVI.01283-20 (2020).
- 486 25 Tortorici, M. A. & Velesler, D. Structural insights into coronavirus entry. *Adv*  
487 *Virus Res* **105**, 93-116, doi:10.1016/bs.aivir.2019.08.002 (2019).
- 488 26 Gu, H. *et al.* Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine  
489 efficacy. *Science*, doi:10.1126/science.abc4730 (2020).
- 490 27 Dinno, K. H., 3rd *et al.* A mouse-adapted model of SARS-CoV-2 to test  
491 COVID-19 countermeasures. *Nature*, doi:10.1038/s41586-020-2708-8 (2020).
- 492 28 Liu, Y. *et al.* Functional and Genetic Analysis of Viral Receptor ACE2  
493 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.  
494 2020.2004.2022.046565, doi:10.1101/2020.04.22.046565 %J bioRxiv (2020).
- 495 29 Yuan, Y. *et al.* Cryo-EM structures of MERS-CoV and SARS-CoV spike  
496 glycoproteins reveal the dynamic receptor binding domains. *Nat Commun* **8**,  
497 15092, doi:10.1038/ncomms15092 (2017).
- 498 30 Henderson, R. *et al.* Glycans on the SARS-CoV-2 Spike Control the Receptor  
499 Binding Domain Conformation. *bioRxiv*, doi:10.1101/2020.06.26.173765  
500 (2020).
- 501 31 Pallesen, J. *et al.* Immunogenicity and structures of a rationally designed  
502 prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A* **114**,  
503 E7348-E7357, doi:10.1073/pnas.1707304114 (2017).

- 504 32 Tang, G. *et al.* EMAN2: an extensible image processing suite for electron  
505 microscopy. *J Struct Biol* **157**, 38-46, doi:10.1016/j.jsb.2006.05.009 (2007).
- 506 33 Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure  
507 determination in RELION-3. *Elife* **7**, doi:10.7554/eLife.42166 (2018).
- 508 34 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced  
509 motion for improved cryo-electron microscopy. *Nat Methods* **14**, 331-332,  
510 doi:10.1038/nmeth.4193 (2017).
- 511 35 Zhang, K. Gctf: Real-time CTF determination and correction. *J Struct Biol*  
512 **193**, 1-12, doi:10.1016/j.jsb.2015.11.003 (2016).
- 513 36 Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local  
514 resolution of cryo-EM density maps. *Nat Methods* **11**, 63-65,  
515 doi:10.1038/nmeth.2727 (2014).
- 516 37 Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein  
517 structures and complexes. *Nucleic Acids Res* **46**, W296-W303,  
518 doi:10.1093/nar/gky427 (2018).
- 519 38 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory  
520 research and analysis. *J Comput Chem* **25**, 1605-1612, doi:10.1002/jcc.20084  
521 (2004).
- 522 39 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics.  
523 *Acta Crystallogr D Biol Crystallogr* **60**, 2126-2132,  
524 doi:10.1107/S0907444904019158 (2004).
- 525 40 Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for  
526 macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**,  
527 213-221, doi:10.1107/S0907444909052925 (2010).
- 528 41 Chen, V. B. *et al.* MolProbity: all-atom structure validation for  
529 macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* **66**,  
530 12-21, doi:10.1107/S0907444909042073 (2010).
- 531 42 Barad, B. A. *et al.* EMRinger: side chain-directed model and map validation  
532 for 3D cryo-electron microscopy. *Nat Methods* **12**, 943-946,  
533 doi:10.1038/nmeth.3541 (2015).

534 **Acknowledgements**

535 We thank the Tsinghua University Branch of China National Center for Protein  
536 Sciences (Beijing) for the cryo-EM facility and the computational facility support,  
537 and J. Lei, X. Li, F. Yang, J. Wen and S. Zhang for technical support. This work was  
538 supported by funds from the National Key Plan for Scientific Research and  
539 Development of China (2016YFD0500307 and 2020YFC0845900) and Tsinghua  
540 University Spring Breeze Fund (2020Z99CFY031).

541


542 **Author contributions**

543 S.Z. and J.Y. carried out protein expression, purification, electron microscopy sample  
544 preparation and data collection with assistance from L.T. S.Z. and S.Q. performed  
545 image processing and model building with the help of J.Y. and J.Z. S.Z. and S.Q.  
546 performed SPR experiments with assistance from J.L. S.S. conducted pseudovirus  
547 entry assays. X.W. and J.Y. conceived, designed and directed the study. X.W., S.Z.,  
548 S.Q., J.Y. and L.Z. analyzed the structures, made the figures and wrote the manuscript.

549

550 **Conflict of interest statement**

551 The authors declare no competing interests



552

553 **Fig.1 Overall structures of the RaTG13 and PCoV\_GX spike glycoproteins. (A)**

554 Overall structures of RaTG13 and PCoV\_GX spike glycoproteins shown in side view

555 (upper panel) and top view (lower panel). Three monomers of the RaTG13 spike are

556 colored magenta, red, and blue, respectively; three monomers of the PCoV\_GX spike

557 are colored hot pink, green and cyan, respectively. The cryo-EM maps are shown as a


558 semitransparent surface. The trigonal axes are shown as black dashed lines. Visible

559 segments of each monomer are labeled accordingly. The cap and stalk parts are

560 partitioned by gray dashed lines. **(B)** Schematic representation of the RaTG13 spike


561 monomer structural domains. The domains of RaTG13 are shown as boxes with the

562 width related to the length of the amino acid sequence. The start and end amino acids  
563 of each segment are labeled. The position of the S1/S2 and S2' cleavage sites are  
564 indicated by scissors. NTD, N-terminal domain; CTD, C-terminal domain; SD1,  
565 subdomain 1; SD2, subdomain 2; UH, upstream helix; FP, fusion peptide; CR,  
566 connecting region; HR1, heptad repeat 1; CH, central helix; BH,  $\beta$ -hairpin; SD3,  
567 subdomain 3. **(C)** Schematic representation of the PCoV\_GX spike monomer  
568 structural domains. The abbreviations of elements are the same as in **B**. **(D)** Cartoon  
569 diagrams depicting three orientations of the spike monomer colored as in **B** and **C**. As  
570 the RaTG13 and PCoV\_GX spike monomers have extremely similar structures, thus  
571 only the RaTG13 spike monomer was used to show the detailed architecture.



572

573 **Fig.2 RBD structures of the RaTG13 and PCoV\_GX spike proteins.** (A) The  
574 RaTG13 and PCoV\_GX RBDs are shown in side view. The RaTG13 RBD core is  
575 colored in magenta and the RBM in cyan; the PCoV\_GX RBD core is colored in  
576 green and the RBM in cyan. Disulfide bonds are shown as red sticks with residues  
577 labeled. (B) Structural alignment of the RaTG13, PCoV\_GX and SARS-CoV-2 (PDB  
578 ID:6M0J; core colored in wheat) RBDs. Aligned structures are shown in two  
579 orientations.




580

581 **Fig.3 The relationship between binding affinity and sequence variation in**  
 582 **different spike proteins. (A)** Binding curves of immobilized human ACE2 with the  
 583 SARS-CoV-2 (left panel), PCoV\_GX (middle panel) or RaTG13 (right panel) RBD.  
 584 Data are shown as different colored lines and the best fit of the data to a 1:1 binding  
 585 model is shown in black. **(B)** Sequence alignment of the RBMs from the  
 586 SARS-CoV-2, PCoV\_GX and RaTG13 spike proteins (left panel). Residues Y449  
 587 and Y505 in the SARS-CoV-2 RBM and the corresponding residues in the RaTG13  
 588 and PCoV\_GX RBMs are marked in red. The RBD of SARS-CoV-2 (PDB ID:6M0J)  
 589 shown as a cartoon (right panel). Residues in the SARS-CoV-2 RBM that contact  
 590 hACE2 are indicated by red dots. Residues 486, 493, 498 and 501 in the RBM of  
 591 SARS-CoV-2 are shown as blue dots. **(C)** Principal residues at the SARS-CoV-2  
 592 RBD-hACE2 (PDB ID:6M0J) and RaTG13 RBD-hACE2 interfaces. Hydrogen  
 593 bonds between SARS-CoV-2 Y449 and hACE2 D38 and Q42 would be abolished  
 594 after Y to F mutation in the RaTG13 RBM (two leftmost panel). Hydrogen bonds  
 595 between SARS-CoV-2 Y505 and hACE2 E37 and R393 would be abolished after Y  
 596 to H mutation in the RaTG13 RBM (two rightmost panels).

597





598

599 **Fig.4 The residues and glycans interacting with one RBD of the different spikes.**

600 (A) The residues and glycans interacting with one RBD are shown as salmon spheres.

601 The RaTG13 RBD is colored in magenta, PCoV\_GX RBD in green, SARS-CoV-2

602 (PDB ID: 6VXX) RBD in wheat, and SARS-CoV-2 (PDB ID: 6ZGE) RBD in marine;

603 remaining regions shown in gray. (B) Detailed structures of the RBD-glycans

604 interface are shown. The RaTG13, PCoV\_GX and SARS-CoV-2 (PDB ID:


605 6ZGE/6VXX) RBDs are colored the same as in A. Glycans are shown as red sticks

606 and Asn-linked glycans are labeled. Sequence alignment of the SARS-CoV-2,

607 RaTG13 and PCoV\_GX RBD-interacting glycosylation sites is shown in the bottom

608 panel. Some sequences between the three sites are omitted and indicated by black dots.

609 Amino acid positions of asparagines are indicated above the sequences according to  
610 SARS-CoV-2. Asparagines (N) are colored red and threonines (T) are colored blue.



611

612 **Fig.5 Binding affinities and cell entry of the different spikes.** (A) Binding curves  
 613 of immobilized hACE2 with the SARS-CoV-2, PCoV\_GX or RaTG13 spike. Data are  
 614 shown as different colored lines and the best fit of the data to a 1:1 binding model is  
 615 shown in black. (B) The cell entry efficiencies of pseudotyped viruses as measured by  
 616 luciferase activity. SARS-CoV-2, PCoV\_GX and RaTG13 pseudotyped viruses were

617 used to infect hACE2-transfected HEK293 cells. (C) The representative micrographs  
618 and 2D classification results of negative-staining EM. Both spikes were incubated  
619 with 4-fold molar ratio of hACE2. The red box shows the complex of the PCoV\_GX  
620 spike with hACE2.